Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
Stopped Observed event rate was below the rate required to meet study objectives.
Conditions
- Non-Small Cell Lung Cancer
Interventions
- OTHER: None (Observational Study)
Sponsor
AstraZeneca